Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655896 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
A Phase 2 study of Scleroderma, Diffuse, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT06655896 is a Phase 2 study of Scleroderma, Diffuse that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 96 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT06655896, a Phase 2 study of Scleroderma, Diffuse, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Conditions Studied
Interventions
- BIOLOGICAL rapcabtagene autoleucel
- BIOLOGICAL rituximab
Study Locations (20)
California
- UCLA - Los Angeles
- UCSF - San Francisco
- UCSF - San Francisco
- Sutter Health Network - San Pablo
Other
- Novartis Investigative Site - Graz
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Olomouc
New South Wales
- Novartis Investigative Site - Camperdown
- Novartis Investigative Site - Darlinghurst
Florida
- FL Medical Clinic Orlando Health - Zephyrhills
Illinois
- Northwestern University - Chicago
Iowa
- University Of Iowa - Iowa City
Massachusetts
- Boston Medical Center - Boston
Michigan
- Michigan Med University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2032-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06655896
The ClinicalTrials.gov registry entry for NCT06655896 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Scleroderma, Diffuse appearing as the primary indexed condition, and to 2 interventions - of which rapcabtagene autoleucel is the first listed.
NCT06655896 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Other, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06655896 about?
NCT06655896 is a clinical study titled "Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis". The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
What is the current status of trial NCT06655896?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2024-10-29. Estimated completion is 2032-08-30.
What conditions does trial NCT06655896 study?
This clinical trial studies the following conditions: Scleroderma, Diffuse.
What interventions are being tested in trial NCT06655896?
The interventions under investigation include: rapcabtagene autoleucel (BIOLOGICAL), rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06655896?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06655896 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma, Diffuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.